Alteogen Inc

Overview

Alteogen Inc (Alteogen) is a biotech company that develops proprietary antibody-drug conjugate and antibody biosimilars. The company’s pipeline products include ALT-P1, ALT-Q2, ALT-Q5, ALT-P7, ALT-L9 and ALT-L2. Its products are used for long-acting human growth hormone, long-acting factor Vlla, breast/gastric cancer ADC, ovarian cancer ADC, eyelea biosimilar and herceptin biosimilar. Alteogen also develops NexP Fusion technology and NexMab ADC technology. The company’s NexP Fusion technology is a second-generation long-acting technology which uses DNA recombination and human A1AT (alpha-1 antitrypsin) protein in human blood as the protein carrier. It operates its office in Seoul, South Korea. Alteogen is headquartered in Daejeon, South Korea.
Key Stats
Address
Yuseong-daero 1628beon-gil, Yuseong-gu, Yuseong-gu, DAEJEON, South Korea
Headquarters

South Korea

Contact

82 42 3848780

No of Employees

46

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

196170 [KOSDAQ]

Revenue (2020)

$36 m

43.4% (2020 vs 2019)
Net Income (2020)

$-1 m

-66.7% (2020 vs 2019)
Net Profit Margin

-2 %

5% (2020 vs 2019)
Market Cap *

$2,949 m

EPS *

$-0

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Alteogen IncCelltrion IncCellumed Co LtdAprogen pharmaceuticals Inc
Key Information
Headquarters South Korea South Korea South Korea South Korea
Headquarter City DAEJEON INCHEON SEOUL SEONGNAM
Headquarter State/Province - - - -
No. of Employees 46 1,074 74 96
Entity Type Public Public Public Public

Products & Services

Alteogen is a biotech company. Key products offered by the company include the following:

Products
  • Products
  • Pipeline:
  • ALT-P1 - Long-Acting Human Growth Hormone
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Contracts/Agreements In February, the company and Merck entered into an agreement to manufacture next-generation biotherapeutics.
2018 Contracts/Agreements In March, the company entered into a joint venture agreement with Malaysia’s Inno Bio Ventures…
2008 Incorporation/Establishment The company was founded.

Locations


Ceres F&D Inc

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
25 Feb 2021 Alteogen Enters Manufacturing Agreement with Merck for Recombinant Biologics Contract Service Agreement Alteogen Inc Merck KGaA
07 Jan 2021 Intas Pharma Enters into Licensing Agreement with Alteogen Licensing Agreement Intas Pharmaceuticals Ltd Alteogen Inc
14 Dec 2020 Alteogen to Raise USD68.99 Million in Private Placement of Shares Equity Offering Alteogen Inc
04 Aug 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
24 Jun 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
20 Mar 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

9

Active Jobs

3

Posted

0

Closed

Job Trends

Latest Jobs

Job title Company Country
New Alteogen Co., Ltd. Corporate Research Institute Master's Researcher Recruitment (~9/10) Alteogen Inc Colombia
Alteogen Co., Ltd. Recruitment of RA/QA personnel (~21.09.03) Alteogen Inc Colombia
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar